# Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/LRMR/larimar-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference
Ticker: LRMR
Company: Larimar Therapeutics
Source: Larimar Therapeutics
Published: 2025-12-18 13:00 EST
Original Source URL: https://investors.larimartx.com
## Summary

BALA CYNWYD, Pa. , Dec. 18, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will present and participate in

## Article Body
BALA CYNWYD, Pa. , Dec. 18, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will present and participate in
## Recent Company News
- 2026-05-14 11:00 EST — [Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update](https://biopharmsignal.com/news/LRMR/larimar-therapeutics-reports-first-quarter-2026-financial-and-business-update) — Source: Larimar Therapeutics
- 2026-04-30 20:05 EST — [Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia](https://biopharmsignal.com/news/LRMR/larimar-therapeutics-publishes-cross-species-findings-supporting-skin-as-a-surrogate-for-the-measurement-of-frataxin-in-tissues-clinically-relevant-to-friedreich-s-ataxia) — Source: Larimar Therapeutics
- 2026-03-19 11:00 EST — [Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results](https://biopharmsignal.com/news/LRMR/larimar-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results) — Source: Larimar Therapeutics
- 2026-03-04 21:05 EST — [Larimar Therapeutics to Participate in Upcoming Investor Conferences in March](https://biopharmsignal.com/news/LRMR/larimar-therapeutics-to-participate-in-upcoming-investor-conferences-in-march) — Source: Larimar Therapeutics
- 2026-02-26 01:59 EST — [Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering](https://biopharmsignal.com/news/LRMR/larimar-therapeutics-announces-pricing-of-upsized-100-million-underwritten-public-offering) — Source: Larimar Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)